462222AD2

Ionis Pharmaceuticals, Inc.

Could not find a ticker for this position, may be a filing error

A biotech pioneer that designs medicines that target RNA—the body's genetic messengers—to treat diseases that were long considered "undruggable." Its medicines include SPINRAZA for spinal muscular atrophy and newer launches like WAINUA, TRYNGOLZA, and DAWNZERA, used mainly by patients with rare, neurological, and cardiometabolic conditions. Founded in 1989, it was originally named Isis Pharmaceuticals after the Egyptian goddess of healing, but renamed itself Ionis in 2015 to shake an unfortunate association with the militant group of the same name.

CONVERTIBLEUnderlying: IONSCUSIP: 462222AD2HealthcareUS1 derivative reporter

0% Convertible Senior Notes due 04/01/2026

Ownership Activity Financials Filings

Insiders

Ranked by how much each holding moved in the last 5 years

Insider

Monia Brett PChief Executive Officer, Director · 79 transactions

245.6K+390%

Granted 1.04M · Sold 895.5K

Berthelsen Spencer RDirector · 14 transactions

156.1K+45.5%

Granted 78.4K · Sold 32.0K

Baroldi JosephEVP, Chief Business Officer · 49 transactions

98.9K—

Granted 158.5K · Sold 113.2K

Hougen Elizabeth LEVP, Finance & CFO · 32 transactions

82.7K+89.6%

Granted 412.2K · Sold 326.5K

Bennett C FrankEVP, Chief Scientific Officer · 49 transactions

80.6K+89%

Granted 294.3K · Sold 230.0K

Schneider EugeneEVP, Chf Clinical Develop Ofcr · 32 transactions

77.1K+701.5%

Granted 177.2K · Sold 131.3K

Birchler BrianEVP, Corp and Development Ops · 28 transactions

67.5K—

Granted 101.3K · Sold 59.7K

Swayze EricEVP Research · 55 transactions

64.3K—

Granted 184.8K · Sold 164.4K

Kordasiewicz Holly B.EVP, Chief Development Officer · 8 transactions

63.4K—

Granted 72.0K · Sold 65.0K

O'Neil Patrick R.EVP CLO & General Counsel · 60 transactions

61.5K+130.2%

Granted 358.0K · Sold 324.8K

Muto Frederick TDirector · 3 transactions

61.1K+52.5%

as of Jul 2022

Granted 19.2K

Geary Richard SEVP, Chief Development Officer · 48 transactions

59.7K+42.3%

Granted 205.2K · Sold 166.1K

Herman Joan EDirector · 12 transactions

58.1K+308.4%

Granted 74.1K · Sold 44.0K

Hayden Michael RDirector · 10 transactions

56.3K—

as of Jul 2025

Granted 21.9K · Bought 20.0K

Loscalzo JosephDirector · 23 transactions

54.1K+123.6%

Granted 134.2K · Sold 123.8K

Wender Joseph HDirector · 21 transactions

52.0K-60.7%

Granted 55.9K · Sold 128.8K

Parshall B LynneDirector · 23 transactions

51.9K-29.3%

Granted 147.3K · Sold 167.6K

Cadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper Ofc · 14 transactions

35.8K+481.1%

as of Feb 2024

Granted 46.8K · Sold 15.5K

Klein Joseph IIIDirector · 44 transactions

31.6K—

Granted 143.5K · Sold 150.7K

Diaz Allene M.Director · 14 transactions

28.7K—

Granted 62.4K · Sold 58.6K

Jenne KyleEVP, Chf GL Pdt Str Ofcr · 10 transactions

23.7K—

Granted 68.7K · Sold 47.0K

Devers Shannon L.EVP, Chief Human Resources Ofc · 33 transactions

16.3K—

Granted 122.7K · Sold 114.3K

Reikes Peter NDirector · 1 transaction

14.2K+14.3%

as of Oct 2021

Granted 1.8K

Yang Michael J.Director · 3 transactions

7.9K—

Granted 7.9K

Insider	Stake change	Holds now	Granted / vested	Bought	Sold
Monia Brett PChief Executive Officer, Director · 79 transactions	+390%	245.6K	1.04M	—	895.5K
Berthelsen Spencer RDirector · 14 transactions	+45.5%	156.1K	78.4K	—	32.0K
Baroldi JosephEVP, Chief Business Officer · 49 transactions	—	98.9K	158.5K	—	113.2K
Hougen Elizabeth LEVP, Finance & CFO · 32 transactions	+89.6%	82.7K	412.2K	—	326.5K
Bennett C FrankEVP, Chief Scientific Officer · 49 transactions	+89%	80.6K	294.3K	—	230.0K
Schneider EugeneEVP, Chf Clinical Develop Ofcr · 32 transactions	+701.5%	77.1K	177.2K	—	131.3K
Birchler BrianEVP, Corp and Development Ops · 28 transactions	—	67.5K	101.3K	—	59.7K
Swayze EricEVP Research · 55 transactions	—	64.3K	184.8K	—	164.4K
Kordasiewicz Holly B.EVP, Chief Development Officer · 8 transactions	—	63.4K	72.0K	—	65.0K
O'Neil Patrick R.EVP CLO & General Counsel · 60 transactions	+130.2%	61.5K	358.0K	—	324.8K
Muto Frederick TDirector · 3 transactions	+52.5%	61.1Kas of Jul 2022	19.2K	—	—
Geary Richard SEVP, Chief Development Officer · 48 transactions	+42.3%	59.7K	205.2K	—	166.1K
Herman Joan EDirector · 12 transactions	+308.4%	58.1K	74.1K	—	44.0K
Hayden Michael RDirector · 10 transactions	—	56.3Kas of Jul 2025	21.9K	20.0K	—
Loscalzo JosephDirector · 23 transactions	+123.6%	54.1K	134.2K	—	123.8K
Wender Joseph HDirector · 21 transactions	-60.7%	52.0K	55.9K	—	128.8K
Parshall B LynneDirector · 23 transactions	-29.3%	51.9K	147.3K	—	167.6K
Cadoret-Manier OnaizaEVP,Chf GL Pdt Str & Oper Ofc · 14 transactions	+481.1%	35.8Kas of Feb 2024	46.8K	—	15.5K
Klein Joseph IIIDirector · 44 transactions	—	31.6K	143.5K	—	150.7K
Diaz Allene M.Director · 14 transactions	—	28.7K	62.4K	—	58.6K
Jenne KyleEVP, Chf GL Pdt Str Ofcr · 10 transactions	—	23.7K	68.7K	—	47.0K
Devers Shannon L.EVP, Chief Human Resources Ofc · 33 transactions	—	16.3K	122.7K	—	114.3K
Reikes Peter NDirector · 1 transaction	+14.3%	14.2Kas of Oct 2021	1.8K	—	—
Yang Michael J.Director · 3 transactions	—	7.9K	7.9K	—	—

Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.